GT Metabolic Solutions

Focus: GT Metabolic Solutions is a legacy biotechnology company founded in 1892, specializing in magnetic compression anastomosis technology for metabolic diseases and obesity treatment. The company operates as a public entity focused on innovative surgical device and diagnostic solutions.

Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About GT Metabolic Solutions

AI assessmentNot Hiring

No open roles listed right now. Follow GT Metabolic Solutions to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

13 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

PYLORI-CHEK BREATH TEST

H. pylori detection/diagnostic

LOE Approaching

Aging diagnostic product nearing patent expiration; likely a shrinking revenue contributor.

Help build intelligence for GT Metabolic Solutions

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in a niche high-growth market (obesity/metabolic disease) with multiple magnet-based device platforms in development
130+ year operational history and public company status provides stability and established infrastructure
Therapeutic focus on obesity aligns with one of pharma's fastest-growing market segments

Watch Out For

No active job postings listed, signaling either low hiring velocity or potential organizational constraints
Two core products (Pylori-Chek, Helicosol) both approaching loss of exclusivity with no disclosed LOE dates, creating revenue cliff risk
Pipeline programs lack traditional pharma phase designation (all listed as N/A), suggesting device/procedural classification with unclear regulatory pathway

Generated by Claude from GT Metabolic Solutions's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Second H. pylori-focused product also facing imminent loss of exclusivity; combined portfolio suggests legacy diagnostic focus under pressure.

Pipeline & Clinical Trials

Magnet System

Anastomosis, Functional

N/A

Clinical Trials (1)

NCT07431723Creation of Compression Anastomosis Using the GT Metabolic Magnet System

N/A

Side-to-side duodenal-ileal anastomosis

Anastomosis, Surgical

N/A

Clinical Trials (1)

NCT06928545MagDI U.S. Registry

N/A

Magnet System

Gastric Outlet Obstruction

N/A

Clinical Trials (1)

NCT07317076GT Metabolic Magnet System in Adults With Gastrointestinal Disorders

N/A

Magnet System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT06232746Magnetic Jejuno-Ileal Diversion Study ("MJI Study")

N/A

Magnet System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT06467955MagDI Canada Study

N/A

Magnet System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT06473831MagDI Australia Study

N/A

MAGNET System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT07085741Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico

N/A

MAGNET System, DI Bio-fragmentable

Type 2 Diabetes

N/A

Clinical Trials (1)

NCT05692518MagDI Diversion Feasibility Study

N/A

MagGJ System

Obesity

N/A

Clinical Trials (1)

NCT06073457Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")

N/A

Magnet System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT06613724Magnetic Duodeno-Ileal Chile Study

N/A

Magnet System

Obesity (Disorder)

N/A

Clinical Trials (1)

NCT07317115Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes

N/A

Side-to-side anastomosis duodeno-ileostomy diversion procedure

Obesity

N/A

Clinical Trials (1)

NCT05322122Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System

N/A

Magnet System, DI Biofragmentable

Obesity

N/A

Clinical Trials (1)

NCT06613711MagDI Italian Study

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1892

Portfolio: 2 approved products, 13 clinical trials

Top TAs: Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

LOE Approaching2 (100%)

2 total products

Therapeutic Area Focus

Metabolic Diseases

10 pipeline

Marketed

Pipeline

GT Metabolic Solutions

About GT Metabolic Solutions

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Pipeline & Clinical Trials

Open Jobs (0)